835 related articles for article (PubMed ID: 18594512)
1. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
Tammela T; Zarkada G; Wallgard E; Murtomäki A; Suchting S; Wirzenius M; Waltari M; Hellström M; Schomber T; Peltonen R; Freitas C; Duarte A; Isoniemi H; Laakkonen P; Christofori G; Ylä-Herttuala S; Shibuya M; Pytowski B; Eichmann A; Betsholtz C; Alitalo K
Nature; 2008 Jul; 454(7204):656-60. PubMed ID: 18594512
[TBL] [Abstract][Full Text] [Related]
2. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling.
Tammela T; Zarkada G; Nurmi H; Jakobsson L; Heinolainen K; Tvorogov D; Zheng W; Franco CA; Murtomäki A; Aranda E; Miura N; Ylä-Herttuala S; Fruttiger M; Mäkinen T; Eichmann A; Pollard JW; Gerhardt H; Alitalo K
Nat Cell Biol; 2011 Sep; 13(10):1202-13. PubMed ID: 21909098
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Laakkonen P; Waltari M; Holopainen T; Takahashi T; Pytowski B; Steiner P; Hicklin D; Persaud K; Tonra JR; Witte L; Alitalo K
Cancer Res; 2007 Jan; 67(2):593-9. PubMed ID: 17234768
[TBL] [Abstract][Full Text] [Related]
4. VEGFR-3 in adult angiogenesis.
Witmer AN; van Blijswijk BC; Dai J; Hofman P; Partanen TA; Vrensen GF; Schlingemann RO
J Pathol; 2001 Nov; 195(4):490-7. PubMed ID: 11745682
[TBL] [Abstract][Full Text] [Related]
5. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling.
Benedito R; Rocha SF; Woeste M; Zamykal M; Radtke F; Casanovas O; Duarte A; Pytowski B; Adams RH
Nature; 2012 Mar; 484(7392):110-4. PubMed ID: 22426001
[TBL] [Abstract][Full Text] [Related]
6. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM
Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249
[TBL] [Abstract][Full Text] [Related]
8. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization.
Tvorogov D; Anisimov A; Zheng W; Leppänen VM; Tammela T; Laurinavicius S; Holnthoner W; Heloterä H; Holopainen T; Jeltsch M; Kalkkinen N; Lankinen H; Ojala PM; Alitalo K
Cancer Cell; 2010 Dec; 18(6):630-40. PubMed ID: 21130043
[TBL] [Abstract][Full Text] [Related]
9. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.
Shibuya M
J Biochem; 2013 Jan; 153(1):13-9. PubMed ID: 23172303
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
12. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
[TBL] [Abstract][Full Text] [Related]
13. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
Chen HM; Tsai CH; Hung WC
Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
[TBL] [Abstract][Full Text] [Related]
14. AIP1 mediates vascular endothelial cell growth factor receptor-3-dependent angiogenic and lymphangiogenic responses.
Zhou HJ; Chen X; Huang Q; Liu R; Zhang H; Wang Y; Jin Y; Liang X; Lu L; Xu Z; Min W
Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):603-15. PubMed ID: 24407031
[TBL] [Abstract][Full Text] [Related]
15. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.
Lee WS; Pyun BJ; Kim SW; Shim SR; Nam JR; Yoo JY; Jin Y; Jin J; Kwon YG; Yun CO; Nam DH; Oh K; Lee DS; Lee SH; Yoo JS
MAbs; 2015; 7(5):957-68. PubMed ID: 25942475
[TBL] [Abstract][Full Text] [Related]
16. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
Pytowski B; Goldman J; Persaud K; Wu Y; Witte L; Hicklin DJ; Skobe M; Boardman KC; Swartz MA
J Natl Cancer Inst; 2005 Jan; 97(1):14-21. PubMed ID: 15632376
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
[TBL] [Abstract][Full Text] [Related]
18. Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis.
Lee S; Rho SS; Park H; Park JA; Kim J; Lee IK; Koh GY; Mochizuki N; Kim YM; Kwon YG
J Clin Invest; 2017 Feb; 127(2):457-471. PubMed ID: 27991863
[TBL] [Abstract][Full Text] [Related]
19. Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy.
D'Amico G; Korhonen EA; Anisimov A; Zarkada G; Holopainen T; Hägerling R; Kiefer F; Eklund L; Sormunen R; Elamaa H; Brekken RA; Adams RH; Koh GY; Saharinen P; Alitalo K
J Clin Invest; 2014 Feb; 124(2):824-34. PubMed ID: 24430181
[TBL] [Abstract][Full Text] [Related]
20. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis.
Achen MG; Williams RA; Minekus MP; Thornton GE; Stenvers K; Rogers PA; Lederman F; Roufail S; Stacker SA
J Pathol; 2001 Feb; 193(2):147-54. PubMed ID: 11180159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
